DJI46,558.47-0.26%
GDAXI23,447.29-0.60%
GSPC6,632.19-0.61%
HSI25,465.60-0.98%
IXIC22,105.36-0.93%
N22553,819.61-1.16%
AAPL250.12-2.21%
AMZN207.67-0.89%
CL98.71+3.11%
EURUSD1.1423-0.82%
GBPUSD1.3223-0.93%
GC5,061.70-1.25%
GOOG301.46-0.58%
JPM283.44+0.19%
META613.71-3.83%
MSFT395.55-1.58%
NVDA180.25-1.59%
TSLA391.20-0.96%
DJI46,558.47-0.26%
GDAXI23,447.29-0.60%
GSPC6,632.19-0.61%
HSI25,465.60-0.98%
IXIC22,105.36-0.93%
N22553,819.61-1.16%
AAPL250.12-2.21%
AMZN207.67-0.89%
CL98.71+3.11%
EURUSD1.1423-0.82%
GBPUSD1.3223-0.93%
GC5,061.70-1.25%
GOOG301.46-0.58%
JPM283.44+0.19%
META613.71-3.83%
MSFT395.55-1.58%
NVDA180.25-1.59%
TSLA391.20-0.96%
DJI46,558.47-0.26%
GDAXI23,447.29-0.60%
GSPC6,632.19-0.61%
HSI25,465.60-0.98%
IXIC22,105.36-0.93%
N22553,819.61-1.16%
AAPL250.12-2.21%
AMZN207.67-0.89%
CL98.71+3.11%
EURUSD1.1423-0.82%
GBPUSD1.3223-0.93%
GC5,061.70-1.25%
GOOG301.46-0.58%
JPM283.44+0.19%
META613.71-3.83%
MSFT395.55-1.58%
NVDA180.25-1.59%
TSLA391.20-0.96%
LIVE
USA Yahoo Finance EN

Where Will Eli Lilly Stock Be in 10 Years?

Mar 07, 2026 &03350707202631; 16:35 UTC finance.yahoo.com Trending 2/5
Read original on finance.yahoo.com ↗
Positive for markets
Sentiment score: +65/100
Moderate impact Long-term (months)
WHAT THIS MEANS
Eli Lilly's long-term stock trajectory depends on sustained growth in GLP-1 diabetes and obesity treatments, pipeline expansion, and market penetration. The company faces patent cliff risks post-2030 but maintains strong R&D capabilities and pricing power in specialty pharmaceuticals.
AI CONFIDENCE
72% High
SENTIMENT GAUGE
NEWS POWER SCORE
AFFECTED ASSETS
Eli Lilly
LLYStock
Expected to rise
Strong GLP-1 franchise growth, robust pipeline, and expanding addressable market in obesity and diabetes treatments support long-term appreciation potential
S&P 500
^GSPCIndex
Expected to rise
Eli Lilly's significant weighting in S&P 500 healthcare sector provides positive contribution to index performance over 10-year horizon
PRICE HISTORY
Loading chart...
SUGGESTED ACTION
Long-term investors should monitor LLY's pipeline progress, GLP-1 market share sustainability, and patent cliff mitigation strategies. Consider accumulating on dips while tracking competitive pressures from Novo Nordisk and Ozempic biosimilars entering market post-2030.
KEY SIGNALS
GLP-1 market dominance and revenue growth trajectoryPatent expiration risks for key drugs post-2030Pipeline strength in obesity, diabetes, and Alzheimer's treatmentsPricing power in specialty pharmaceuticalsM&A opportunities and strategic partnershipsRegulatory approval success rates
SECTORS INVOLVED
HealthcarePharmaceuticalsBiotechnology
Analysis generated on Mar 09, 2026 at 17:29 UTC
Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Yahoo Finance. Always conduct your own research and consult a qualified financial advisor before making investment decisions.